FDA sees rapid uptick in drug and biologic submissions with AI/ML components
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyResearch, Design and Development